Open AccessIs MPP a good prognostic factor in stage III lung adenocarcinoma with EGFR exon 19 mutation?
Author(s) -
Tian Zhang,
Jing Wang,
Yanjun Su,
Xi Chen,
Yan Qu,
Qi Li,
Leina Sun,
Yuwen Wang,
Puchun Er,
Qingsong Pang,
Ping Wang
Publication year - 2017
Publication title -
oncotarget
Language(s) - English
Resource type - Journals
SCImago Journal Rank - 1.373
H-Index - 127
ISSN - 1949-2553
DOI - 10.18632/oncotarget.16505
Subject(s) - exon , medicine , adenocarcinoma , mutation , cancer research , epidermal growth factor receptor , oncology , stage (stratigraphy) , lung cancer , lung , pathology , cancer , genetics , biology , gene , paleontology
Epidermal growth factor receptor (EGFR) is a transmembrane glycoprotein encoded by a gene located in the short arm of chromosome 7. This study aimed to investigate the clinicopathologic characteristics of classic EGFR exon mutation in Chinese patients with TMN stage III lung adenocarcinoma who received radical surgery. A total of 1,801 lung adenocarcinomas were analyzed for mutations in EGFR; 35% exhibited mutation of classic EGFR exons. Clinical and pathologic characteristics of patients with EGFR exon 19 mutation were compared with those who harbored EGFR exon 21 mutation. Patients with EGFR exon 19 mutation had a higher overall survival (OS, p=0.023) than those harboring EGFR exon 21 mutation. Our results demonstrated that patients with a micropapillary pattern (MPP) pathologic type in EGFR exon 19 mutation had a higher OS (p=0.022), and patients with exon 19 mutation were more sensitive to EGFR-tyrosine kinase inhibitors (p=0.032). The results of the current study can be used in decision-making regarding the treatment of patients with classic EGFR exon mutations.